Objectives: To evaluate the significant role played by biofilms during prosthetic vascular material infections (PVMIs).
Introduction
Staphylococcus aureus biofilm development plays a significant role in the difficulties encountered when treating prosthetic vascular material infections (PVMIs). Previously published data have provided evidence that S. aureus, classically considered an extracellular pathogen, can also invade and survive inside immune cells, including phagocytes. Such a survival mechanism could be responsible for a lack of antibiotic efficacy and the possibility of relapse of chronic infections. 1 This hypothesis was suggested because of the results of in vitro co-culture models and data are scarce reporting such in vivo interactions between S. aureus and mammalian tissues in the particular setting of PVMIs.
We recently developed an in vivo mouse model of S. aureus PVMI evaluating the efficacy of different antibiotic regimens on six clinical and collection S. aureus strains. 2 Although antibiotic MICs were similar for all strains, their antibacterial efficacy was, overall, limited and strain-dependent. For instance, mice infected with MRSA BCB8 were cured with daptomycin monotherapy whereas this antibiotic demonstrated no efficacy for MSSA ATCC 27217.
To better understand these surprising results, we used the same PVMI model to visualize the S. aureus biofilm structures in situ, whether they were treated with antibiotics or not. In particular, we focused on the interaction between immune cells and bacteria embedded in biofilms to address whether intracellular S. aureus could be an explanation for the lack of antibiotic efficacy in PVMIs.
Materials and methods
Based on our previous data 2 on six S. aureus clinical and collection strains, we selected the two most representative bacterial strains: MSSA ATCC 27217 and MRSA BCB8, isolated from blood cultures. Both strains were fully susceptible to the antibiotics tested (MICs were: daptomycin 0.125 mg/L for MRSA and 0.25 mg/L for MSSA, vancomycin 1 mg/L for both strains and rifampicin ,0.006 mg/L for both strains). The following antistaphylococcal agents were provided by drug companies and prepared following label instructions: vancomycin (Sandoz, Levallois-Perret, France), daptomycin (Novartis Pharma SAS, Rueil-Malmaison, France) and rifampicin (SanofiAventis, Paris, France). The in vivo experiments were approved by the French Ministry of Research Review Board and have been described elsewhere. 2 Briefly, at least four 4-week-old female Swiss mice (RjOrl/SWISS, Immediately after the procedure, the Dacron V R patches were removed and visualized with a confocal laser scanning microscope (Leica TCS SP5, Leica Microsystems, France). Images were acquired using a %63 oil-immersion objective lens with a numerical aperture of 1.4. For all the experiments, the size of the confocal images was 512%512 pixels (either 215%215 lm 2 or 82%82 lm 2 ), recorded with a z-step of 1 lm and a %3 zoom. For each biofilm, at least four different regions were analysed and biofilm structures were compared by direct observation. For this purpose, nucleic acids (in both bacterial and eukaryotic cells) were stained with Syto9 V R (Invitrogen), which is able to penetrate all cells, and propidium iodide (PI, Invitrogen), which can only penetrate cells with a damaged membrane. Syto9
V R and PI were excited with an argon laser at 488 and 543 nm, respectively, and their fluorescence emissions were collected between 500 and 600 nm for Syto9
and between 640 and 750 nm for PI.
To simultaneously visualize the bacteria, immune cells (neutrophils and macrophages) and antibiotics, all were specifically stained to ensure well-discriminated fluorescence emissions. Neutrophils were stained with Ly-6G
V R /mouse-specific marker (GR-1, Pacific Blue TM conjugate RB6-8C5), excited using an argon laser at 361 nm; the fluorescence emission was collected in the range 400-450 nm. Macrophages were stained with F4/80 V R macrophage-specific antibody (Alexa Fluor V R 647 conjugate BM8), excited with a neon laser at 633 nm; the fluorescence emission was collected in the range 650-750 nm. BODIPY-FL V R -daptomycin (kindly provided by Cubist Pharmaceuticals) and BODIPY-FL V R -vancomycin (from Sigma) were excited at 488 nm and the fluorescence emission was collected in the range 500-550 nm.
Results

Typical structures of in vivo MSSA-and MRSA-infected Dacron
V R patches are illustrated in Figure 1 . As expected for an infection site, high numbers of bacteria and immune cells were trapped in a dense and thick reticular extracellular matrix (Figure 1a and b) . We also noted that there were only a few damaged cells after Dacron V R removal from mice. When antibiotics were applied, the observed structures were antibiotic-and strain-dependent. In the case of antibiotic ineffectiveness, the visualization of Dacron V R patches was very similar to the controls (Figure 1e , f, i and l). In contrast, the material surface displayed lightened structures with only scattered immune cells when antibiotics were effective (Figure 1c , d, g, h, j and k). In more detail, for MRSA BCB8, vancomycin did not show any significant effect on biofilms compared with the control samples, in contrast to rifampicin and daptomycin. For MSSA 27217, the effect of daptomycin as well as vancomycin was more limited, yielding bacterial structures close to the control ones whereas rifampicin was the most active antibiotic. The combination of rifampicin with vancomycin appeared to be very effective in the overall structure lightening, which was not the case for the daptomycin/rifampicin combination. These results all correlate with bactericidal activity measurements (Table S1 , available as Supplementary data at JAC Online). 
MRSA BCB8 Figure 1 . The structures of biofilms developed on Dacron V R in vivo are antibiotic dependent. Visualization of Dacron V R -related S. aureus biofilms depending on antibiotic treatments by confocal laser scanning microscopy: controls (a and b); daptomycin (c and d); vancomycin (e and f); rifampicin (g and h); daptomycin/rifampicin (i and j); and vancomycin/rifampicin (k and l). Green staining, Syto9
V R (live cells); red staining, PI (membrane-damaged cells); white arrows, reticular structures corresponding to the extracellular matrix; red arrows, single bacteria included within this structure; blue arrows, eukaryotic cells; yellow arrows, intracellular S. aureus. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
Intramacrophagic S. aureus in vascular infection
JAC them penetrated macrophages carrying live S. aureus bacteria (Figure 2b ).
Discussion
The visualization of antibiotics within biofilm-associated bacteria may contribute to our understanding of the differential effects of antistaphylococcal agents on material-associated S. aureus infections; this was the purpose of our study. Dacron V R implants with biofilms were grown in living mice and then visualized by confocal fluorescence microscopy immediately after the mice were euthanized. This procedure allowed us to: (i) observe in situ interactions of live bacteria with the prosthetic vascular material but also with the host cells (PMNLs and macrophages), widely present at the infection site; (ii) correlate the biofilm structures with antibacterial activity of antibiotics (daptomycin, vancomycin and their combination with rifampicin); and (iii) highlight live S. aureus bacteria inside the macrophages present at the biofilm sites where antibiotics do not penetrate these immune cells.
These in vivo results are different from those found in in vitro biofilm models, 6 which do not permit observation of the interactions between bacteria and host cells occurring in vivo. 7 Most in vivo models rely on bacterial counts within infected materials, but do not include imaging techniques visualizing the direct effect of antibiotics on biofilms developed in vivo. 8 The S. aureus PVMI mouse model presented herein may provide new data in this field.
Our results do not reveal significant change in the biofilm structures from one S. aureus isolate to another but do show a differential effect of antistaphylococcal agents. We confirm the dramatic efficacy of rifampicin in comparison with other treatments, [8] [9] [10] probably owing to its well-known excellent intracellular penetration and activity. Unexpectedly, daptomycin, often referred to as one of the most active antistaphylococcal agents on biofilm, 11, 12 yielded only very limited effects. The antibiotic was active on MRSA BCB8-related biofilm on Dacron V R but not on MSSA 27217-related biofilm. These results support previous findings showing that there is no difference between vancomycin and daptomycin activities in vitro 13 or in vivo. 14 We do not have a definitive explanation for such differences of daptomycin efficacy according to the staphylococcal strain but we have already reported that in an in vitro model 15 tolerance toward this molecule may be related to a physiological change involving structural modifications of the membrane, a strain-dependent process. Previous studies have reported the capability of S. aureus to survive within osteoblasts in the context of bone and joint infections, resulting in persistent and relapsing infections. 16 We visualize here the same possible capacity to survive inside host cells (i.e. macrophages) during S. aureus PVMIs. An important consequence of this process is that intramacrophagic S. aureus are able to escape the phagolysosome, leading to free replication in the cytoplasm. They can trigger cell death mechanisms in their host cells, to proliferate and disseminate, but, on the other hand, they can also activate anti-apoptotic programmes to persist hidden in an intracellular location and thus, induce chronic or relapsing infections. 1 In addition, an intramacrophagic location could represent a shelter for S. aureus against antibiotics: the less able to penetrate host eukaryotic cells they are, the less efficient they could be.
Thus, we hypothesize that the persistence of S. aureus inside macrophages during PVMIs could be an explanation for the relative inefficacy of antibiotics used without surgery during these infections, and for the high risk of relapse when the infected material is not removed. This may also explain why antibiotic efficacy could be different according to the strain involved, since the capability of S. aureus to invade mammalian cells may vary from one strain to another. 17 This study has some limitations. The first is the site of vascular prosthetic material implantation. For evident technical reasons, it was impossible to implant our Dacron V R along the vascular system. Some authors have already described an extra-anatomic animal model, with implantation of vascular material in a subcutaneous position, to evaluate different prophylactic procedures to prevent PVMIs. 18 Nevertheless, in a clinical setting, most PVMIs occur from the wound or from an adjacent infectious focus and not through a haematogenous route. 19 Therefore, the infection process usually starts along the external part of the vascular prosthesis, not the endoluminal layer. In this context, our model reproduces this natural history of infection and may be reasonably used to evaluate different antibiotic regimens for PVMI treatment.
The limited number of evaluated bacterial strains could be a second weakness of our work. This study follows previously published work 2 dealing with the antibiotic activity on six different S. aureus strains in our mouse model of PVMI. Similar results were obtained for MSSA and MRSA strains and thus, we selected the two morerepresentative bacterial strains to allow more demonstrable differences in antibiotic action regarding in vivo biofilm developed on Dacron V R . In conclusion, this in vivo mouse model of S. aureus PVMIs allows direct observation of the impact of major antistaphylococcal agents on Dacron V R -related biofilm. We visualized intramacrophagic S. aureus on the biomaterial and we hypothesize that intramacrophagic S. aureus could also be present during PVMIs in clinical settings and may explain why bacteria may persist, and cause relapse, even after prolonged and appropriate antibacterial therapy. More studies are needed, but we can postulate that the use of antibiotics that are active against biofilm-embedded and intracellular bacteria, such as rifampicin, could be a very good option in PVMIs.
